Fennec Pharmaceuticals (TSE:FRX) Stock Price Passes Above Fifty Day Moving Average – Here’s What Happened

Fennec Pharmaceuticals Inc. (TSE:FRX) shares passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of C$7.55 and traded as high as C$8.87. Fennec Pharmaceuticals shares last traded at C$8.87, with a volume of 121 shares changing hands.

Analyst Ratings Changes

Separately, Stephens raised shares of Fennec Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 18th.

Fennec Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 1,040.68, a current ratio of 8.02 and a quick ratio of 10.17. The company has a market cap of C$242.68 million, a price-to-earnings ratio of 88.70 and a beta of 0.25. The firm has a 50 day simple moving average of C$7.55 and a 200-day simple moving average of C$7.64.

Insider Buying and Selling

In other news, Director Rostislav Christov Raykov bought 25,000 shares of the company’s stock in a transaction on Friday, December 20th. The stock was bought at an average cost of C$3.87 per share, with a total value of C$96,840.00. Also, Senior Officer Robert Christopher Andrade acquired 15,816 shares of the stock in a transaction dated Monday, November 18th. The stock was acquired at an average cost of C$3.43 per share, with a total value of C$54,248.88. In the last ninety days, insiders acquired 41,612 shares of company stock valued at $157,868. 16.20% of the stock is currently owned by insiders.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.